Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
Advanced Primary Liver Cancer
DRUG: Elemene
Objective response rate and/or 1-year survival rate, Objective response rate.The proportion of patients who had a best response rating of complete response and partial response., 1 year
Disease control rate(DCR), Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease., 1 year|Progression-free survival(PFS), Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause, 1 year|Overall survival(OS), Overall survival.The time of patient from randomization to death caused by any cause, 3 year|Quality of Life Questionnaire (QLQ), Quality of Life Questionnaire Core 30, 3 year|the rate of incidence of adverse events, NCI CTC AE 4.03, 3 year
Patients with advanced primary liver cancer will be enrolled in the trial , then separated randomly into two group. One group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin , another group treated with Systematic Chemotherapy including Oxaliplatin. The purpose of the study is to evaluate the effect and safety of the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer